Lipitor MDL Approved for Type 2 Diabetes Litigation: McSweeney / Langevin Advising Woman Diagnosed with Type 2 Diabetes Following Lipitor use

Federal litigation involving Pfizer's cholesterol-lowering drug Lipitor has been consolidated before a single judge in South Carolina.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInShare on PinterestEmail a friend
Lipitor Lawyer

Statins such as Lipitor have been alleged to cause type 2 diabetes in women

I can feel how frustrated these women are because they all tried to eat right, exercise, etc. Unfortunately, one of the things they did was take statins, and it appears there may be a link between cholesterol lowering drugs and diabetes

(PRWEB) March 25, 2014

The law firm McSweeney / Langevin continues to advise women regarding potential legal claims regarding a possible link between use of Lipitor and the development of type 2 diabetes. Recently, federal litigation involving Pfizer, and plaintiffs alleging Lipitor caused type 2 diabetes, was centralized in South Carolina following Transfer Order relative to MDL No. 2502, In Re: Lipitor (Atorvastatin Calcium) Marketing, Sales Practices and Products Liability Litigation (No. II)).

McSweeney / Langevin’s investigation into Lipitor injuries has been ongoing since the February 28, 2012 Food and Drug Administration's Safety Announcement regarding important safety changes to the labels of statins such as Pfizer's Lipitor, Merck's Zocor and AstraZeneca's Crestor. The FDA announcement follows several studies linking statins to an increased risk of diabetes for women.

A January 2012 JAMA Internal Medicine study revealed 50 to 79 year old who took statins were 48% more likely to suffer from type 2 diabetes when compared to women who did not.

Additional studies have also indicated a potential link between statin use and type 2 diabetes in women.

A February 17, 2010 study conducted by The Lancet, an independent and unaffiliated medical organization, found statin therapy was associated with a 9% increased risk for diabetes.

A March 23, 2010 study conducted by the American College of Cardiology concluded statin treatment resulted in "significant increases in fasting insulin and glycated hemoglobin levels consistent with insulin resistance and ambient glycemia in hypercholesterolemic patients."

A November 2, 2010 Atherosclerosis study found daily statin users have a "significantly increased risk" of developing diabetes.

A July of 2013 petition to the United States Judicial Panel on Multidistrict Litigation requesting centralization of all Lipitor cases was denied. (MDL No. 2459 In Re: Lipitor (Atorvastatin Calcium) Marketing, Sales Practices and Products Liability Litigation). Although the petition was denied, the panel indicated the petition would be granted if more lawsuits were filed in the future.

Since the July 2013 petition was denied, the number of Liptor lawsuits has doubled and a second petition before the United States Judicial Panel on Multidistrict Litigation was grated. (MDL No. 2502 In Re: Lipitor (Atorvastatin Calcium) Marketing, Sales Practices and Products Liability Litigation (No. II)).

In the MDL No. 2502 Transfer Order, the Panel indicated the Lipitor cases involve common questions of fact, and that centralization will serve the convenience of parties and witnesses and promote the just and efficient conduct of this litigation.

Attorneys Rhett A. McSweeney and David M. Langevin have discussed statin use and type 2 diabetes with a number of women throughout the United States. Langevin states, "the one thing I hear time and time again from the women I have talked with is how surprised they were when they received the diabetes diagnosis. Most of these women have low BMIs and are non-smokers. In addition, most have been eating right and excising in an attempt to keep their cholesterol low. I can feel how frustrated these women are because they all tried to do the right things to try and reduce their cholesterol. Unfortunately, one of the things they did was take statins, and it appears there may be a link between cholesterol lowering drugs and diabetes. If true, it is sad because nobody would trade a slightly reduced cholesterol level for type 2 diabetes."

About the personal injury law firm of McSweeney / Langevin

With the sole purpose of helping the injured, the personal injury law firm McSweeney / Langevin ensures victims and victims’ families are adequately compensated for wage loss, medical expenses and pain and suffering. While most firms have you speak with an “investigator” or “case manager,” McSweeney / Langevin connects people with one if its attorneys who will be handling your case. The firm handles personal injury cases related to dangerous/defective pharmaceutical drugs, dangerous/defective medical devices, and serious/catastrophic injury claims. For more information, visit http://www.westrikeback.com or call 1-800-888-4425.


Contact

Follow us on: Contact's Google Plus